Clene Featured in BioMedWire Podcast, CEO Discusses Novel Approach to Treating Neurodegenerative Diseases
Clene (NASDAQ: CLNN) featured in BioMedWire Podcast, CEO discusses unique approach to treating neurodegenerative diseases such as ALS and MS, highlighting potential for improved patient survival rates.
This news matters as it highlights a unique approach to treating neurodegenerative diseases such as ALS and MS, potentially improving survival rates for patients. The company’s focus on improving mitochondrial health and protecting neuronal function has significant implications for the treatment of these devastating diseases.